Genetic Determinants of the Hypokalemic and Hyperglycemic Effect of Albuterol Inhalation
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00162487|
Recruitment Status : Unknown
Verified October 2008 by Hadassah Medical Organization.
Recruitment status was: Recruiting
First Posted : September 13, 2005
Last Update Posted : October 29, 2008
Several studies have indicated that albuterol administered either intravenously or by inhalation can significantly reduce plasma potassium concentration in patients suffering from chronic renal failure.In conjunction with the decrease in potassium concentration a modest rise in glucose concentration is usually noted. These metabolic effects are characterized by rapid onset occurring as early as 3-5 minutes following salbutamol administration and lasting for at least 1 hour.
The role played by ß2AR polymorphisms in determining the bronchial and vascular response to ß2AR agonist drugs, have been confirmed by several studies.
The purpose of the present study is to examine possible causal relationships between genetically based alteration in the structure of ß2AR and the metabolic effects of inhaled albuterol.
|Condition or disease||Intervention/treatment|
|Hyperkalemia Chronic Renal Failure||Drug: Albuterol (1,200 μg) through metered-dose inhaler|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||150 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of β2 Genetic Polymorphisms and the Effect of Albuterol Inhalation on Potassium and Glucose Plasma Concentration|
|Study Start Date :||August 2002|
- The extent of decrease in plasma potassium concentration
- The extent of increase in plasma glucose concentration
- Plasma concentration of albuterol
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00162487
|Hadassah Medical Organization||Recruiting|
|Jerusalem, Israel, 91120|
|Contact: Arik Tzukert, DMD 00 972 2 6776095 email@example.com|
|Contact: Hadas Lemberg, PhD 00 972 2 6777572 firstname.lastname@example.org|
|Principal Investigator: Yoseph Caraco, MD|
|Principal Investigator:||Yoseph Caraco, MD||Hadassah Medical Organization|